Trial · NCT04094961
Ixazomib + Pomalidomide + Dexamethasone In MM
NCT04094961, Phase 1, Phase 2, Active not recruiting, Omar Nadeem, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ixazomib + Pomalidomide + Dexamethasone In MM. Trials, record NCT04094961. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04094961
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ixazomib + Pomalidomide + Dexamethasone In MM
- NCT number
- NCT04094961
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 52 participants, actual
- Lead sponsor
- Omar Nadeem, MD
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse
- Interventions
- Ixazomib, Pomalidomide, Dexamethasone
- First posted
- 2019-09-19
- Last updated
- 2026-03-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with dose limiting toxicity | 21 Days | 3 - 24 safety evaluable patients will be enrolled in up to 4 dose levels of ixazomib, pomalidomide and dexamethasone. |
| Primary | Overall Response Rate | 28 days | Response will be evaluated using a Simon optimal two-stage design |
| Secondary | Time to Progression | time from first dose of study drug to progression, censored at date last known progression-free for those who have not progressed, whichever came first, assessed up to 60 months | Estimated using the method of Kaplan-Meier. |
| Secondary | Progression Free Survival | time from first dose of study drug to the disease progression or death from any cause, censored at date last known progression-free for those who have not progressed or died, whichever came first, assessed up to 60 months | Estimated using the method of Kaplan-Meier. |
| Secondary | Duration of Response | time from response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died, whichever came first, assessed up to 60 months | Estimated using the method of Kaplan-Meier. |
| Secondary | Overall Survival | time from first dose of study drug to death or date last known alive, whichever came first, assessed up to 60 months | Estimated using the method of Kaplan-Meier. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04094961
GET https://conductscience.org/api/trials/v1/NCT04094961/registered